BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24441146)

  • 1. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
    Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
    Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
    Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
    Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Díaz-Beyá M; Labopin M; Maertens J; Aljurf M; Passweg J; Dietrich B; Schouten H; Socié G; Schaap N; Schwerdtfeger R; Volin L; Michallet M; Polge E; Sierra J; Mohty M; Esteve J; Nagler A;
    Br J Haematol; 2020 Jun; 189(5):920-925. PubMed ID: 32020596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.
    Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
    Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
    Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
    Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
    [No Abstract]   [Full Text] [Related]  

  • 8. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
    Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
    BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
    Qin H; Malek S; Cowell JK; Ren M
    Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
    Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
    [No Abstract]   [Full Text] [Related]  

  • 11. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML).
    Logan GE; Mor-Vaknin N; Braunschweig T; Jost E; Schmidt PV; Markovitz DM; Mills KI; Kappes F; Percy MJ
    Blood Cells Mol Dis; 2015 Jan; 54(1):123-31. PubMed ID: 25128083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).
    Visconte V; Shetty S; Przychodzen B; Hirsch C; Bodo J; Maciejewski JP; Hsi ED; Rogers HJ
    Int J Lab Hematol; 2017 Aug; 39(4):409-417. PubMed ID: 28318095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities.
    Baldazzi C; Luatti S; Marzocchi G; Grassi A; Cavo M; Testoni N
    Cancer Genet; 2022 Apr; 262-263():35-39. PubMed ID: 34979355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel variant translocation (1;9)(p22;q34) resulting in a DEK/NUP214 fusion gene in a patient with acute myeloid leukemia: A case report.
    Hao Q; Zhang Q; Li C; Wei S; Li Q; Song Y; Mi Y
    Oncol Lett; 2017 Dec; 14(6):7021-7024. PubMed ID: 29344131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview.
    Chi Y; Lindgren V; Quigley S; Gaitonde S
    Arch Pathol Lab Med; 2008 Nov; 132(11):1835-7. PubMed ID: 18976025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
    Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
    Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophil chimerism in the differential diagnosis between DEK-NUP214-positive acute myeloid leukaemia relapse and chronic graft-versus-host disease.
    e Moura de Souza CL; Bub CB; Torres MA; Velloso ED; Silveira PA; Correia RP; Bacal NS; Mangueira CL; Fernandes JF; Odone Filho V; Hamerschlak N; Campregher PV
    J Clin Pathol; 2015 Nov; 68(11):950-2. PubMed ID: 26193901
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
    Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
    PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Moraleda PP; Gerbing RB; Raimondi SC; Hirsch BA; Ravindranath Y; Lange B; Woods WG; Gamis AS; Meshinchi S
    Br J Haematol; 2014 Jul; 166(2):254-259. PubMed ID: 24661089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.